SPECIALTY GUIDELINE MANAGEMENT

ONPATTRO (patisiran)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

<u>FDA-Approved Indications</u>
Onpattro is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:
A. Initial Requests:
   1. Testing or analysis confirming a mutation of the TTR gene
   2. Documentation confirming the member demonstrates signs and symptoms of polyneuropathy
B. Continuation Requests: Chart notes or medical record documentation confirming the clinical benefit from Onpattro

III. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a neurologist, geneticist, or physician specializing in the treatment of amyloidosis.

IV. CRITERIA FOR INITIAL APPROVAL

Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis
Authorization of 12 months may be granted for treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (also called transthyretin-type familial amyloid polyneuropathy [ATTR-FAP]) when all of the following criteria are met:
A. The diagnosis is confirmed by detection of a mutation of the TTR gene.
B. Member exhibits clinical manifestations of ATTR-FAP (e.g., amyloid deposition in biopsy specimens, TTR protein variants in serum, progressive peripheral sensory-motor polyneuropathy).
C. The requested medication will not be used in combination with inotersen (Tegsedi), tafamidis (Vyndaqel, Vyndamax) or vutrisiran (Amvuttra).

V. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for the continued treatment of ATTR-FAP when all of the following criteria are met:
A. The member must have met all initial authorization criteria.
B. The member must have demonstrated a beneficial response to treatment with Onpattro therapy compared to baseline (e.g., improvement of neuropathy severity and rate of disease progression as demonstrated by the modified Neuropathy Impairment Scale+7 (mNIS+7) composite score, the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score, polyneuropathy disability (PND) score, FAP disease stage, manual grip strength).

REFERENCES

1. Onpattro [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; January 2023.
2. Adams, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5; 379(1):11-21.
3. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 8:31.
4. Sekijima Y. Hereditary Transthyretin Amyloidosis. 2001 Nov 5 [Updated 2021 June 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1194/.   Accessed March 15, 2023.